U.S., EU Back Pharma in Denying Access to Lifesaving COVID Products

A compromise effort to waive intellectual-property rights for vaccines, treatments, and tests will do little to expand supply, experts believe.


Fortify your mind! Join the Prospect today

Support The American Prospect's independent, nonprofit journalism by becoming a member today. You will stay engaged with the best and brightest political and public policy reporting and analyses, and help keep this website free from paywalls and open for all to read. Our membership levels offer a range of perks including an opt-in to receive the print magazine by mail.